Healthy Aging

1. BioSignal Quick Verdict

• Does it work? (What actually maintains healthspan.) Yes — for a specific, unglamorous core. The

best-evidenced levers are physical activity and exercise (aerobic + resistance/strength + balance training) [R2, R3, R6, R7, R8], adequate protein and a healthy dietary pattern [R11, R12], treating cardiovascular risk (blood pressure, lipids) [R22, R25], vaccination [R23, R24], and staying cognitively and socially engaged [R15, R18]. These maintain strength, mobility, independence, and function — the substance of healthy aging.

• What it does NOT do (headline the nulls). No pill "reverses aging." **Vitamin D supplementation does not

reduce fractures in unselected older adults [R14]; intensive blood-pressure control did not significantly reduce probable dementia (it reduced mild cognitive impairment) [R20]; "brain-training" improves the trained task but does not reliably transfer to everyday function [R17]; and anti-aging supplements — NAD⁺ precursors (NMN/NR), resveratrol, and metformin-for-aging — are not established** to extend human healthspan [R27, R28].

• How much? (The core prescription.) 150–300 min/week of moderate aerobic activity, **muscle-

strengthening ≥2 days/week, and, for older adults, multicomponent balance training [R2, R3]; ~1.0–1.2 g/kg/day protein [R11]; a Mediterranean-style diet** [R12]; keep vaccinations current [R23, R24].

• Who benefits most? Everyone as they age — and the frailest most of all. High-intensity progressive

resistance training improved strength and mobility even in frail nonagenarians [R6]; falls-prevention exercise most helps those at risk [R8].

• Lifespan ≠ healthspan. This monograph is about functional, independent years, not maximal lifespan.

Some interventions extend life, some extend function, some do neither, and the popular assumption that they are all the same is false.

• Overall confidence: High that exercise (strength, function, falls) and vaccination maintain

healthspan [R6, R7, R8, R23, R24]; Moderate-High for protein, dietary pattern, blood-pressure and lipid control, and the associations between physical activity, social connection, and lower mortality (largely observational) [R4, R11, R12, R18, R22, R25]; Moderate for multidomain cognitive interventions [R15]; Mixed for brain-training (trained gains without reliable everyday transfer) [R17]; Not Established / Contradicted for BP-for-dementia [R20], anti-aging supplements [R27, R28], and vitamin-D fracture prevention [R14].

• Evidence stability: High for the exercise and vaccination cores and for the major nulls; Moderate

for the cognitive and social-intervention evidence, where trials are ongoing.

• One-sentence bottom line: *Healthy aging is built — reproducibly and at any age — from exercise

(especially strength and balance), adequate protein and a good diet, cardiovascular-risk and preventive care, and cognitive and social engagement; it is not bought from anti-aging supplements, and lifespan should never be confused with healthspan.*

• Most common misconception: *That "anti-aging" is a product you can buy, and that living longer and living

well are the same thing. The evidence points to behaviors and prevention, not pills, and to function*, not just years [R14, R27, R28].

2. Executive Summary

Healthy aging is about healthspan, not lifespan. The World Health Organization frames Healthy Ageing as developing and maintaining the functional ability that enables wellbeing in older age — the capacity to move, think, and engage independently — rather than the mere accumulation of years [R1]. This distinction is the spine of the monograph: an intervention can extend life without extending healthy life, or improve function without changing lifespan, and the two must never be conflated. The central question here is narrow and practical: what is actually supported by high-quality evidence to keep people functional, independent, and well as they age?

The strongest answer is exercise. Physical activity guidelines converge on 150–300 minutes per week of moderate aerobic activity, muscle-strengthening at least twice weekly, and — specifically for older adults — multicomponent balance training [R2, R3]. The causal evidence is unusually strong for a lifestyle factor: progressive resistance training reliably increases muscle strength and improves physical function across systematic reviews of scores of trials [R7], and did so even in frail nursing-home residents in their 90s, where a multinutrient supplement alone did nothing [R6]. Exercise prevents falls — a leading cause of lost independence — reducing the rate of falls by about 23%, with balance and functional exercise the active ingredient [R8]. Higher physical activity and higher cardiorespiratory fitness are associated with substantially lower mortality in large cohorts, though this portion of the evidence is observational [R4, R5].

Muscle, protein, and diet are the substrate. Aging erodes muscle (sarcopenia, now defined by low strength first [R10]) and can tip into frailty, a validated phenotype predicting falls, disability, and death [R9]. Countering it requires both the training stimulus and the building blocks: older adults benefit from more protein than the adult RDA (~1.0–1.2 g/kg/day) [R11], and a Mediterranean dietary pattern reduced major cardiovascular events by roughly 30% in a landmark RCT [R12]. Body composition matters, but not as a simple "lose weight" message: in older adults the lowest mortality is associated with a higher BMI than in midlife, and unintentional weight loss is a danger sign, not a goal [R13].

Brain and social health are real, but the evidence is more calibrated. A multidomain lifestyle intervention (diet, exercise, cognitive training, vascular monitoring) preserved cognition in at-risk older adults in the FINGER trial [R15], and the Lancet Commission estimates that ~45% of dementia is associated with modifiable risk factors [R16] — but that figure is a population-attributable model built on observational data, not a promise of prevention. Commercial cognitive "brain training" improves the trained skills but does not reliably transfer to everyday function [R17]. Social connection is consistently associated with lower mortality, and isolation and loneliness with higher mortality, at effect sizes rivaling classic risk factors — again observational [R18, R19].

Prevention and vaccination are underrated healthspan levers. Controlling blood pressure reduces cardiovascular events and mortality [R22], and statins reduce vascular events including in older adults [R25]; both are strong, actionable, and evidence-based. Vaccines matter more in older adults as immunity wanes: the recombinant zoster vaccine is ~97% effective [R23] and the RSV vaccine is efficacious in adults ≥60 [R24], while influenza vaccination offers more modest, lower-certainty benefit [R26].

And the honest negatives. BioSignal refuses the anti-aging narrative. Vitamin D supplementation did not reduce fractures in generally healthy older adults not selected for deficiency [R14]. Intensive blood-pressure control did not significantly reduce probable dementia (it did reduce mild cognitive impairment) [R20]. And the marquee anti-aging supplements — NAD⁺ precursors (NMN, nicotinamide riboside), resveratrol, and metformin repurposed for aging — are not established to improve human healthspan: they have compelling preclinical stories and, so far, no convincing human outcome evidence, with the dedicated aging trial (TAME) still to report [R27, R28].

BioSignal's overall verdict: healthy aging is built, not bought. It is the sum of well-evidenced, mostly behavioral levers — exercise (especially strength and balance), protein and diet, cardiovascular and preventive care, and cognitive and social engagement — applied consistently and started at any age. The popular "anti-aging" shortcuts are, on current evidence, not established, and the field's honesty about that is itself part of the product.

3. Scientific Mechanisms

Aging is a gradual decline in physiological reserve across systems, and the interventions that preserve healthspan largely work by defending reserve in the tissues that determine function.

Skeletal muscle is central. From roughly the fourth decade, muscle mass and — more importantly — strength and power decline (sarcopenia), driven by loss of motor units, anabolic resistance (muscle responds less to a given protein or exercise stimulus), reduced physical activity, and inflammation. Because strength underpins mobility, balance, and the ability to rise from a chair or recover a stumble, muscle loss is mechanistically upstream of frailty, falls, and loss of independence [R9, R10]. Resistance training directly opposes this by stimulating muscle protein synthesis and neuromuscular adaptation, and dietary protein supplies the substrate; because of anabolic resistance, older adults need more protein per kilogram than younger adults to achieve the same effect [R11].

The cardiovascular and cerebrovascular systems age through arterial stiffening, endothelial dysfunction, and atherosclerosis. Aerobic exercise improves cardiorespiratory fitness, vascular function, and metabolic health; controlling blood pressure and LDL cholesterol reduces the vascular events (heart attack, stroke) that are among the largest causes of lost healthy years [R22, R25]. Because the brain's small vessels are vulnerable to the same insults, vascular risk factors are also dementia risk factors — the mechanistic basis for the Lancet Commission's modifiable-risk model [R16] — although, as the SPRINT MIND trial shows, aggressively treating one factor (blood pressure) does not straightforwardly translate into measurable dementia prevention [R20].

The immune system undergoes immunosenescence — thymic involution, fewer naïve T cells, and "inflammaging" — which raises susceptibility to infection and blunts vaccine responses. This is why older adults suffer disproportionately from influenza, RSV, and reactivated varicella (shingles), and why vaccines specifically formulated for older immunity (adjuvanted or high-antigen) matter [R23, R24].

The brain retains meaningful plasticity into old age. Cognitive and physical activity, vascular health, hearing, and social engagement each plausibly support cognitive reserve — the brain's resilience to pathology. Mechanism makes multidomain lifestyle intervention plausible [R15], but mechanism is not proof: "brain-training" can improve a practiced task through skill acquisition without building general reserve, which is why transfer to everyday function is the honest test — and one it largely fails [R17].

Finally, the anti-aging supplement hypotheses (NAD⁺ repletion, sirtuin activation via resveratrol, metformin's metabolic effects) rest on genuine cellular biology of aging. But mechanism at the cell or in short-lived animals routinely fails to translate to human clinical outcomes, and healthspan is the outcome that matters — so these remain plausible hypotheses awaiting human evidence, not established interventions [R27, R28].

4. Body Systems Affected

• Musculoskeletal (muscle, bone, mobility) — the core of physical healthspan: sarcopenia and frailty erode

strength and mobility [R9, R10]; resistance and balance training and adequate protein preserve them and prevent falls [R6, R7, R8, R11]. (RCT/experimental for training; consensus for protein.)

• Cardiovascular & cerebrovascular — aerobic fitness, blood-pressure and lipid control reduce vascular

events and mortality [R4, R22, R25]; vascular health also underlies dementia risk [R16]. (RCT for BP/lipids; observational for fitness–mortality.)

• Central nervous system (cognition) — multidomain lifestyle intervention shows promise [R15]; modifiable

risk-factor control is associated with lower dementia risk [R16]; brain-training transfer is not established [R17]; BP control did not significantly reduce probable dementia [R20]. (Mixed: RCT + observational.)

• Immune system — immunosenescence raises infection risk; zoster and RSV vaccines are highly effective,

influenza vaccine modestly so [R23, R24, R26]. (RCT.)

• Metabolic & body composition — healthy dietary pattern and activity support metabolic health [R12];

in older adults the BMI–mortality relationship shifts upward, so weight management differs from midlife [R13]. (RCT for diet–CVD; observational for BMI–mortality.)

• Psychosocial & mental health — social connection is associated with survival; isolation and loneliness

with mortality [R18, R19]. (Observational.)

• Skeletal/endocrine (bone) — vitamin D supplementation does not reduce fractures in unselected older

adults [R14]; falls prevention (via exercise) is the better-supported fracture-adjacent lever [R8]. (RCT — negative.)

5. Major Claims — Evidence Evaluation

Each claim carries a stable id (claim-N), a verdict and confidence assigned by the BioSignal Evidence Rating Framework (verdicts §6, confidence §4, decision tree §5), the evidence, conflicting evidence and limitations, and an explicit "what would change our mind." Experimental (RCT) evidence is distinguished from observational association throughout. Claims marked (primary outcome) are the load-bearing conclusions of this hub.

claim-1 — "Regular physical activity maintains function and lowers mortality in older adults." (primary outcome)

• Verdict: Supported. · Confidence: High (function/fitness) / Moderate-High (mortality, observational).
• Evidence. WHO and US guidelines recommend 150–300 min/week moderate aerobic activity plus

muscle-strengthening, and multicomponent balance activity for older adults, based on large evidence reviews [R2, R3]. Higher accelerometer-measured activity and higher cardiorespiratory fitness are associated with markedly lower all-cause mortality in large cohorts (e.g., most-active vs least-active HR ~0.27; fitness with no upper limit of benefit) [R4, R5].

• Evidence quality. Tier 1–2 for the activity–function/fitness link (guidelines, trials); Tier 3 for the

activity/fitness–mortality link (prospective cohorts).

• Conflicting evidence / limitations. The mortality association is observational — reverse causation

(illness reduces activity) and healthy-user confounding cannot be fully excluded, so it is labeled association, not proven causation.

• What would change our mind. RCTs showing no functional benefit of activity, or Mendelian-randomization

evidence overturning the fitness–mortality link.

claim-2 — "Resistance/strength training preserves muscle, strength, and physical function and counters sarcopenia." (primary outcome)

• Verdict: Supported. · Confidence: High.
• Evidence. A Cochrane review of 121 trials (~6,700 older adults) found progressive resistance training

produces large gains in strength (SMD ~0.84) and improves physical function and gait speed [R7]. In frail nursing-home residents (mean age 87), high-intensity resistance training increased strength ~113% and improved mobility, where a nutritional supplement alone did not [R6]. Sarcopenia is now defined by low strength first [R10], the property training most improves.

• Evidence quality. Tier 1–2 (Cochrane review + landmark RCT).
• Conflicting evidence / limitations. Effect sizes for functional endpoints are smaller and more variable

than for strength; adherence and supervision affect results.

• What would change our mind. Large RCTs showing no strength or functional benefit — contrary to a deep,

consistent literature.

• Cross-link: see the Resistance Training monograph (CM-002) for the full treatment.

claim-3 — "Exercise prevents falls in older adults." (primary outcome)

• Verdict: Supported. · Confidence: High.
• Evidence. A Cochrane review found exercise reduces the rate of falls by ~23% (rate ratio 0.77,

high-certainty), with balance and functional exercise the most effective type [R8].

• Evidence quality. Tier 1 (Cochrane review of RCTs).
• Conflicting evidence / limitations. Benefit is clearest for community-dwelling older adults at risk;

program type and dose matter, and generic activity without a balance component is less effective.

• What would change our mind. High-quality trials showing no reduction in fall rate from balance-focused

exercise.

claim-4 — "Older adults need more protein than the adult RDA to preserve muscle." (primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. The PROT-AGE expert position, synthesizing trials and metabolic studies, recommends

~1.0–1.2 g/kg/day for healthy older adults (≥1.2 with exercise; up to 1.5 with illness), above the 0.8 g/kg RDA, to offset anabolic resistance [R11].

• Evidence quality. Tier 1–2 (position paper on trials + balance studies); some endpoints are surrogate

(nitrogen balance, lean mass) rather than hard function.

• Conflicting evidence / limitations. A large RCT of protein supplementation alone in mobility-limited

older men was null without exercise — protein is a substrate, not a stimulus; it works paired with training.

• What would change our mind. Adequately powered RCTs showing higher protein confers no muscle/functional

benefit even alongside resistance training.

• Cross-link: see the Protein Intake monograph (CM-001).

claim-5 — "A healthy dietary pattern (Mediterranean) supports cardiovascular and healthy aging." (primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. In the PREDIMED RCT (7,447 high-risk adults), a Mediterranean diet with extra-virgin olive

oil or nuts reduced major cardiovascular events by ~30% (HR ~0.69–0.72) versus a control diet [R12].

• Evidence quality. Tier 2 (large RCT with a hard CV endpoint; the 2018 corrected-and-republished

analysis).

• Conflicting evidence / limitations. The trial had randomization irregularities corrected in the 2018

re-analysis; broader "healthy aging" and cognitive endpoints rest more on observational data.

• What would change our mind. Replication RCTs failing to reduce CV events, or evidence the effect reflects

confounding rather than the dietary pattern.

claim-6 — "Multidomain lifestyle intervention can preserve cognition in at-risk older adults." (primary outcome)

• Verdict: Supported (modest). · Confidence: Moderate.
• Evidence. The FINGER RCT (a 2-year program of diet, exercise, cognitive training, and vascular

monitoring) improved/maintained cognitive performance versus control in at-risk older adults [R15].

• Evidence quality. Tier 2 (single landmark RCT; effect on a composite cognitive score).
• Conflicting evidence / limitations. A single positive trial; related multidomain trials have been

mixed, the effect size is modest, and dementia (not just test scores) is the endpoint that matters. Worldwide replication (World-Wide FINGERS) is ongoing.

• What would change our mind. Failed replication in adequately powered trials, or confirmation with a

clinical (dementia-incidence) endpoint.

claim-7 — "A large share of dementia is attributable to modifiable risk factors." (primary outcome)

• Verdict: Supported. · Confidence: Moderate-High (as an association-based model).
• Evidence. The Lancet Commission (2024 update) estimates ~45% of dementia is associated with **14

modifiable risk factors** across life (including hypertension, hearing loss, physical inactivity, smoking, diabetes, depression, social isolation, air pollution, less education, obesity, excess alcohol, traumatic brain injury, and — newly — vision loss and high LDL cholesterol) [R16].

• Evidence quality. Tier 1 synthesis, but the headline figure is a population-attributable fraction —

a model built largely on observational associations, assuming causality and independence it cannot fully prove.

• Conflicting evidence / limitations. "Attributable" ≠ "preventable in practice"; single-factor

intervention trials (e.g., BP → dementia, claim-8) have not delivered the modeled reductions. The list is a target set, not a guarantee.

• What would change our mind. Intervention trials showing modifiable-factor control does not lower dementia

incidence, or revised attributable-fraction estimates.

claim-8 — "Treating blood pressure preserves health — and prevents dementia." (primary outcome; split verdict)

• Verdict: cardiovascular events — Supported (Confidence High); probable dementia — **Not

Established (Confidence Limited** — an underpowered null, genuinely uncertain rather than a confident no-effect).

• Evidence. SPRINT showed intensive BP control (<120 vs <140 mmHg) reduced major cardiovascular events

and all-cause mortality [R22]. But SPRINT MIND, its cognitive sub-study, found intensive control did not significantly reduce the primary endpoint of probable dementia (a ~17% reduction that was not statistically significant); it did significantly reduce mild cognitive impairment (~19%) and the combined MCI-plus-dementia endpoint (~15%) [R20].

• Evidence quality. Tier 2 (large RCTs). The dementia null is partly attributable to fewer-than-expected

cases and early trial termination — an underpowered negative, not proof of no effect.

• Conflicting evidence / limitations. Do not overstate either direction: BP control is strongly supported

for cardiovascular health, and suggestive but unproven for cognition.

• What would change our mind. An adequately powered trial showing intensive BP control clearly reduces (or

clearly does not reduce) dementia incidence.

claim-9 — "Social connection supports healthy aging; isolation and loneliness are risks." (primary outcome)

• Verdict: Supported (observational). · Confidence: Moderate-High (association).
• Evidence. Meta-analyses find stronger social relationships associated with ~**50% greater odds of

survival** [R18], and social isolation, loneliness, and living alone each associated with increased mortality [R19] — effect sizes comparable to established risk factors.

• Evidence quality. Tier 3 (large observational meta-analyses).
• Conflicting evidence / limitations. Association, not causation: reverse causation (illness causes

isolation) and confounding are plausible, and RCTs of interventions to reduce loneliness show inconsistent effects on hard outcomes.

• What would change our mind. Trials showing that increasing social connection does not improve health

outcomes, or that the association is explained by confounding.

claim-10 — "Commercial cognitive 'brain training' preserves everyday cognitive function." (deflation)

• Verdict: Mixed (real gains on the trained tasks; transfer to everyday function not established). ·

Confidence: Moderate.

• Evidence. The ACTIVE trial showed cognitive training improves the specifically trained abilities,

but transfer to everyday function was limited [R17]; broader independent reviews reach the same conclusion.

• Evidence quality. Tier 2 (RCT).
• Conflicting evidence / limitations. Trained-task gains are real and can persist; the failure is

generalization to untrained daily function and to dementia prevention.

• What would change our mind. Rigorous trials showing durable transfer to everyday function or reduced

dementia incidence from commercial brain-training.

claim-11 — "Vaccination prevents serious infection in older adults." (primary outcome)

• Verdict: Supported. · Confidence: High (zoster, RSV) / Moderate (influenza).
• Evidence. The recombinant adjuvanted zoster vaccine showed ~97% efficacy against shingles in

adults ≥50 [R23]; the RSV prefusion-F vaccine was efficacious against RSV lower-respiratory disease in adults ≥60 [R24]. Influenza vaccination in older adults probably reduces influenza and influenza-like illness, but evidence for mortality benefit is low-certainty [R26].

• Evidence quality. Tier 1–2 (large RCTs for zoster/RSV; Cochrane review for influenza).
• Conflicting evidence / limitations. Influenza-vaccine effectiveness varies by season and strain match;

the mortality signal is confounded in observational data.

• What would change our mind. New trials lowering the measured efficacy of zoster/RSV vaccines, or

high-certainty evidence resolving the influenza mortality question.

claim-12 — "Statin therapy reduces vascular events in older adults." (primary outcome)

• Verdict: Supported. · Confidence: Moderate-High.
• Evidence. A Cholesterol Treatment Trialists' individual-participant meta-analysis of 28 RCTs found

statins reduce major vascular events per 1 mmol/L LDL reduction across age groups, including older adults [R25].

• Evidence quality. Tier 1 (IPD meta-analysis of RCTs).
• Conflicting evidence / limitations. Direct evidence is thinner for primary prevention above age 75;

benefit is clearest in secondary prevention and in those with vascular risk.

• What would change our mind. Dedicated primary-prevention RCTs in the oldest old showing no net benefit.

claim-13 — "In older adults, a higher BMI than midlife targets is associated with lower mortality." (primary outcome; anti-hype)

• Verdict: Supported (nuanced). · Confidence: Moderate (observational).
• Evidence. A meta-analysis (~198,000 adults ≥65) found being overweight was not associated with excess

mortality in older adults; mortality rose at the lower end of "normal" BMI, and did not increase until BMI >33 [R13].

• Evidence quality. Tier 3 (observational meta-analysis), with reverse causation (illness-related weight

loss) an important caveat.

• Conflicting evidence / limitations. BMI is a crude proxy; function and muscle mass matter more than

weight. This does not license obesity, and central adiposity still carries metabolic risk — but it argues against reflexive weight-loss advice for robust older adults, and against equating "thinner" with "healthier" in late life.

• What would change our mind. Evidence that the higher-BMI survival association is entirely reverse

causation, or that intentional weight loss improves survival in robust older adults.

claim-14 — "Anti-aging supplements (NAD⁺ precursors, resveratrol, metformin-for-aging) extend human healthspan." (deflation; primary contrast)

• Verdict: Not Established. · Confidence: Limited / Insufficient.
• Evidence. NAD⁺ precursors (NMN, nicotinamide riboside) reliably raise NAD⁺ levels but human studies

have not shown that they ameliorate age-related disease or extend healthspan [R28]. Metformin has a plausible geroscience rationale, but its anti-aging efficacy in humans is unproven and awaits the dedicated TAME trial [R27]. Resveratrol's sirtuin story has not translated into human outcome benefit.

• Evidence quality. Tier 5 → 2 mechanistic-to-early-human; no convincing human healthspan-outcome

trials.

• Conflicting evidence / limitations. Strong preclinical and biomarker data exist; the gap is **human

clinical outcomes*. "Not established" means not yet demonstrated, not disproven. A separate, narrower signal deserves honest mention: a daily multivitamin-mineral modestly improved global cognition versus placebo in the COSMOS-Mind RCT [R21] — an emerging, not-yet-replicated* finding, and not evidence for "anti-aging" supplementation.

• What would change our mind. Adequately powered human RCTs showing these agents improve functional,

cognitive, or disability outcomes in aging (e.g., a positive TAME).

claim-15 — "Vitamin D supplementation prevents fractures in older adults." (deflation; primary null)

• Verdict: Contradicted (in unselected, replete older adults). · Confidence: Moderate-High.
• Evidence. In VITAL (25,871 generally healthy adults not selected for deficiency or low bone mass),

vitamin D₃ 2000 IU/day did not reduce total, nonvertebral, or hip fractures versus placebo [R14].

• Evidence quality. Tier 2 (large RCT with a hard endpoint).
• Conflicting evidence / limitations. This applies to replete, unselected populations; correcting

genuine deficiency remains appropriate, and vitamin D with calcium may still matter in institutionalized or deficient older adults. It refutes routine supplementation of healthy older adults for fracture prevention.

• What would change our mind. RCTs in deficient or high-risk populations showing fracture reduction (a

different, narrower question).

• Cross-link: see the Vitamin D Signal Record.

6. Question Resolution (Selected)

• What is the single best thing for healthy aging? **Exercise — especially resistance and balance

training** — has the strongest, broadest, most causal evidence for preserving strength, mobility, independence, and preventing falls, at any age [R6, R7, R8]. Nothing else matches its breadth.

• Can you start too late? No. Benefits are demonstrated even in frail people in their 90s [R6].
• Does living longer mean living better? Not automatically. Lifespan and healthspan are different

outcomes; this monograph targets functional, independent years [R1].

• Do anti-aging supplements work? On current human evidence, no established benefit — NAD⁺ precursors,

resveratrol, and metformin-for-aging are not established for human healthspan [R27, R28].

• Should older adults try to lose weight? Not reflexively. In late life the lowest mortality sits at a

higher BMI, and unintentional weight loss is a warning sign; prioritize muscle and function over the scale [R13].

• Does treating blood pressure prevent dementia? Not established. BP control clearly helps the

heart [R22]; its effect on dementia was not statistically significant (though it reduced mild cognitive impairment) [R20].

• Do brain-training apps prevent decline? They improve the trained task but do not reliably transfer

to everyday function [R17]. Real-world cognitive and social engagement is the better bet [R15, R18].

• Which vaccines matter most? Shingles (recombinant zoster) and RSV have strong RCT support in

older adults; keep influenza and others current too [R23, R24, R26].

7. Confidence Justification

Ratings follow the Evidence Rating Framework (§4 levels, §7 calibration), each capped where capped.

• High is reserved for the exercise core (resistance training and falls prevention — Cochrane reviews

and landmark RCTs) [R7, R8] and the zoster/RSV vaccines (high-efficacy RCTs) [R23, R24], where the causal evidence is strong and replicated.

• Moderate-High, not High, for protein [R11] (partly surrogate endpoints; works only with training),

dietary pattern [R12] (single major RCT with corrected analysis), statins in older adults [R25] (thinner primary-prevention data >75), BP for cardiovascular events [R22], and the observational associations of physical activity, fitness, and social connection with mortality [R4, R5, R18] — capped because these are observational or have one important limitation.

• Moderate for multidomain cognitive intervention [R15] (a single positive RCT amid mixed replication),

BMI–mortality in older adults [R13] (observational, reverse-causation caveat), and brain-training [R17], whose verdict is Mixed (real trained-task gains, no reliable transfer to everyday function).

• Not Established / Contradicted for the anti-aging supplements [R27, R28] (Limited — no human

outcome evidence), BP-for-dementia [R20] (Limited — an underpowered null, genuinely uncertain), and vitamin-D fracture prevention in the unselected [R14] (Moderate-High — a clear, well-powered RCT null). The Framework pairs Contradicted with higher confidence than Not Established, which is why the clean VITAL null earns Moderate-High while the underpowered SPRINT MIND result stays Limited.

No rating is assigned without the documentation above (Framework §12).

8. Remaining Unknowns

Unknowns receive equal visibility with the positive findings:

• Whether single-factor control of dementia risk factors (beyond the modeled attributable fraction)

actually prevents dementia at the population level [R16, R20].

• Whether multidomain interventions reduce dementia incidence (not just test scores), pending

World-Wide FINGERS [R15].

• Whether any anti-aging agent (metformin/TAME, NAD⁺ precursors, senolytics) improves human healthspan

outcomes [R27, R28].

• The optimal protein distribution, dose, and pairing with training in the oldest old [R11].
• Whether interventions that increase social connection causally improve health outcomes [R18, R19].
• The net benefit of statins and intensive BP control in the frail oldest-old, where competing risks

and polypharmacy complicate the picture [R22, R25].

• How to individualize healthy-aging advice across the enormous heterogeneity of older adults (robust vs

frail).

9. Clinical Context (Populations)

• Robust / independent older adults. The full core applies: aerobic + resistance + balance activity,

adequate protein, healthy diet, vaccinations, and cardiovascular-risk management [R2, R3, R11, R12, R22].

• Pre-frail and frail older adults. Exercise still works and matters most here — supervised

progressive resistance and balance training improve strength and mobility even in the frail oldest-old [R6]; ensure adequate protein and screen for reversible contributors to frailty [R9, R11].

• Cognitively at-risk (family history, MCI, vascular risk). Emphasize the modifiable risk factors

(hearing correction, BP, activity, smoking, social engagement) [R16] and multidomain lifestyle programs [R15], while being honest that dementia prevention is not guaranteed [R20].

• Multimorbidity / polypharmacy. Individualize: deprescribe where appropriate, weigh statin and intensive

BP targets against frailty and competing risks [R22, R25], and prioritize function and quality of life.

• Nutritionally vulnerable / underweight. Unintentional weight loss and low BMI are red flags, not

goals [R13]; protect protein and energy intake and investigate causes.

• All older adults. Keep vaccinations current (zoster, RSV, influenza, and others per schedule)

[R23, R24, R26]; correct genuine vitamin-D deficiency while not using routine high-dose supplementation for fracture prevention in the replete [R14].

10. Safety

Healthy-aging interventions are largely safe, but "more" and "aggressive" are not automatically better in older adults, and safety is neither inflated for reassurance nor minimized for a cleaner story.

• Exercise. Very safe and beneficial across the frailty spectrum; the main risks are managed by

progression and supervision (start low, build gradually; balance work reduces — not raises — fall risk over time) [R8]. Screen for unstable cardiac disease before vigorous exertion. The risk of inactivity far exceeds the risk of appropriate activity.

• Intensive cardiovascular treatment. Intensive BP control and statins reduce events but carry real

harms in older adults — hypotension, falls, syncope, acute kidney injury, electrolyte disturbance, polypharmacy interactions — so targets must be individualized, especially in the frail [R22, R25].

• Supplements and "anti-aging" products. Beyond being unproven [R27, R28], high-dose supplements carry

interaction and toxicity risks; routine high-dose vitamin D does not prevent fractures and offers no demonstrated healthy-aging benefit in replete people [R14]. Position supplements as not a substitute for the evidence-based core.

• Protein and diet. Higher protein (~1.0–1.2 g/kg) is safe for older adults with **normal kidney

function**; those with significant chronic kidney disease need individualized targets (see the Protein Intake monograph).

• Weight loss in late life. Unintended or aggressive weight loss risks **muscle and bone loss and

frailty**; any intentional weight loss in older adults should preserve muscle (protein + resistance training) and be clinically supervised [R13].

• When to seek medical evaluation. New falls, unintentional weight loss, functional decline, memory

change, or before starting vigorous exercise with significant cardiovascular disease. These interventions are adjuncts to individualized medical care, never a replacement for it.

11. Practical Guidance (Educational — Not Individual Advice)

12. Special Topics (Concise)

• "Longevity" vs healthspan. Interventions that extend life (e.g., some cardiovascular treatments) are

not identical to those that extend function; the goal here is compressing morbidity — more healthy, independent years — not maximal lifespan [R1].

• Geroscience and the "anti-aging" market. The biology of aging is real and promising, but **no supplement

or drug is yet established to slow human aging; treat NAD⁺ boosters, resveratrol, senolytics, and metformin-for-aging as experimental** [R27, R28].

• Frailty as a reversible target. Frailty is not simply "old age" — it is a measurable, partly

reversible state; exercise and nutrition can move people back toward robustness [R6, R9].

• Sensory health. Correcting hearing (and vision) loss is now on the modifiable-dementia-risk list and

is a cheap, high-value, under-used lever [R16].

13. Healthy-Aging Levers Reference Table (Educational)

14. Common Myths

• "Anti-aging is something you can buy." Not Established. No supplement or drug is proven to slow human

aging; NAD⁺ precursors, resveratrol, and metformin-for-aging are unproven for healthspan [R27, R28].

• "Living longer means living better." False conflation. Lifespan and healthspan differ; this

monograph targets functional years [R1].

• "It's too late to start exercising." Contradicted. Resistance training improved strength and mobility

in frail people in their 90s [R6].

• "Vitamin D pills keep your bones strong as you age." Contradicted in replete, unselected older adults

— vitamin D did not reduce fractures [R14]; correcting true deficiency is a separate, narrower matter.

• "Brain-training games prevent dementia." Not Established — gains don't reliably transfer to everyday

function [R17].

• "Controlling blood pressure prevents dementia." Not Established — it helps the heart [R22] but did

not significantly reduce probable dementia [R20].

• "Older adults should slim down to a 'normal' BMI." Misleading. In late life the lowest mortality sits

at a higher BMI; unintended weight loss is the bigger risk [R13].

• "Strength training is dangerous for the elderly." Contradicted — supervised progressive resistance

training is safe and one of the highest-value interventions [R6, R7].

15. Related Signals

Healthy Aging is the hub of BioSignal Foundations: it synthesizes the domain and links downward to the dedicated monographs and Signal Records, which are never merged into it.

• Related monographs (downward): Resistance Training (CM-002), Protein Intake (CM-001),

Walking (CM-004), Sleep (CM-003), Fiber (CM-005), Hydration (CM-006) — each a pillar of the healthy-aging core.

• Related Signal Records: Creatine and Whey Protein (muscle/sarcopenia, with resistance training);

Collagen (musculoskeletal); Vitamin D (the fracture-prevention null); Magnesium, Omega-3 (cardiometabolic); Caffeine (activity/cognition). (Upward links: each record → Healthy Aging.)

18. Future Research Priorities

• Whether multidomain interventions reduce dementia incidence (World-Wide FINGERS) [R15].
• Whether any geroscience agent (metformin/TAME, NAD⁺ precursors, senolytics) improves human healthspan

outcomes [R27, R28].

• Single-factor dementia-prevention trials to test the modifiable-risk model [R16, R20].
• Optimal exercise-plus-protein protocols and statin/BP targets in the frail oldest-old [R6, R22,

R25].

• Whether social-connection interventions causally improve outcomes [R18, R19].

20. Complete Verified Reference List

Each entry was verified to source during authoring (PubMed, NCBI E-utilities, and journal/publisher pages, cross-checked via Crossref/Europe PMC). PMIDs and DOIs are included where confirmed. This is a curated landmark tier, not an exhaustive bibliography.

• [R1] World Health Organization. World report on ageing and health. Geneva: World Health Organization;
• ISBN 9789241565042. *(Frames Healthy Ageing as maintaining the functional ability that enables

wellbeing. WHO report — no PMID/DOI.)*

• [R2] Bull FC, Al-Ansari SS, Biddle S, et al. *World Health Organization 2020 guidelines on physical

activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451-1462. doi:10.1136/bjsports-2020-102955. PMID: 33239350. (150–300 min/wk moderate aerobic + muscle-strengthening 2+ d/wk; older adults add multicomponent balance training.)*

• [R3] Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA.

2018;320(19):2020-2028. doi:10.1001/jama.2018.14854. PMID: 30418471. (US guideline; same aerobic + strengthening targets; older adults add balance.)

• [R4] Ekelund U, Tarp J, Steene-Johannessen J, et al. *Dose-response associations between accelerometry

measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ. 2019;366:l4570. doi:10.1136/bmj.l4570. PMID: 31434697. (More activity at any intensity associated with lower mortality; observational.)*

• [R5] Mandsager K, Harb S, Cremer P, et al. *Association of cardiorespiratory fitness with long-term

mortality among adults undergoing exercise treadmill testing. JAMA Netw Open. 2018;1(6):e183605. doi:10.1001/jamanetworkopen.2018.3605. PMID: 30646252. (Higher fitness associated with lower mortality, no upper limit; observational.)*

• [R6] Fiatarone MA, O'Neill EF, Ryan ND, et al. *Exercise training and nutritional supplementation for

physical frailty in very elderly people. N Engl J Med. 1994;330(25):1769-1775. doi:10.1056/NEJM199406233302501. PMID: 8190152. (High-intensity resistance training raised strength ~113% in frail nonagenarians; nutrition supplement alone had no effect.)*

• [R7] Liu CJ, Latham NK. *Progressive resistance strength training for improving physical function in

older adults.* Cochrane Database Syst Rev. 2009;(3):CD002759. doi:10.1002/14651858.CD002759.pub2. PMID:

1. (121 trials, ~6,700 older adults: large strength gains, SMD ~0.84; improved function/gait speed.)
2. [R8] Sherrington C, Fairhall NJ, Wallbank GK, et al. *Exercise for preventing falls in older people

living in the community. Cochrane Database Syst Rev. 2019;1(1):CD012424. doi:10.1002/14651858.CD012424.pub2. PMID: 30703272. (Exercise reduces rate of falls ~23%; balance/functional exercise the key type.)*

• [R9] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J

Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156. doi:10.1093/gerona/56.3.m146. PMID: 11253156. (5-component frailty phenotype predicts falls, disability, hospitalization, death.)

• [R10] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. *Sarcopenia: revised European consensus on definition and

diagnosis (EWGSOP2). Age Ageing. 2019;48(1):16-31. doi:10.1093/ageing/afy169. PMID: 30312372. (Low muscle strength is the primary defining feature; confirmed by low muscle quantity/quality.)*

• [R11] Bauer J, Biolo G, Cederholm T, et al. *Evidence-based recommendations for optimal dietary protein

intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-559. doi:10.1016/j.jamda.2013.05.021. PMID: 23867520. (~1.0–1.2 g/kg/day protein for older adults, above the 0.8 RDA; more with exercise/illness.)*

• [R12] Estruch R, Ros E, Salas-Salvadó J, et al. *Primary prevention of cardiovascular disease with a

Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389. PMID: 29897866. (PREDIMED RCT, corrected/republished: ~30% fewer major CV events vs control diet.)*

• [R13] Winter JE, MacInnis RJ, Wattanapenpaiboon N, Nowson CA. *BMI and all-cause mortality in older

adults: a meta-analysis. Am J Clin Nutr. 2014;99(4):875-890. doi:10.3945/ajcn.113.068122. PMID: 24452240. (In older adults, overweight not associated with excess mortality; risk rises at low-normal BMI; observational.)*

• [R14] LeBoff MS, Chou SH, Ratliff KA, et al. *Supplemental vitamin D and incident fractures in midlife

and older adults. N Engl J Med. 2022;387(4):299-309. doi:10.1056/NEJMoa2202106. PMID: 35939577. (VITAL RCT: vitamin D₃ 2000 IU/day did NOT reduce total, nonvertebral, or hip fractures in unselected adults.)*

• [R15] Ngandu T, Lehtisalo J, Solomon A, et al. *A 2 year multidomain intervention of diet, exercise,

cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5. PMID: 25771249. (Multidomain intervention improved/maintained cognition vs control.)*

• [R16] Livingston G, Huntley J, Liu KY, et al. *Dementia prevention, intervention, and care: 2024 report

of the Lancet standing Commission.* Lancet. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0. PMID:

1. (~45% of dementia associated with 14 modifiable risk factors; population-attributable model.)
2. [R17] Ball K, Berch DB, Helmers KF, et al. *Effects of cognitive training interventions with older

adults: a randomized controlled trial (ACTIVE). JAMA. 2002;288(18):2271-2281. doi:10.1001/jama.288.18.2271. PMID: 12425704. (Training improved the targeted abilities; transfer to everyday function limited.)*

• [R18] Holt-Lunstad J, Smith TB, Layton JB. *Social relationships and mortality risk: a meta-analytic

review. PLoS Med. 2010;7(7):e1000316. doi:10.1371/journal.pmed.1000316. PMID: 20668659. (Stronger social relationships associated with ~50% greater odds of survival; observational.)*

• [R19] Holt-Lunstad J, Smith TB, Baker M, Harris T, Stephenson D. *Loneliness and social isolation as risk

factors for mortality: a meta-analytic review. Perspect Psychol Sci. 2015;10(2):227-237. doi:10.1177/1745691614568352. PMID: 25910392. (Isolation, loneliness, living alone each associated with higher mortality; observational.)*

• [R20] SPRINT MIND Investigators for the SPRINT Research Group; Williamson JD, Pajewski NM, Auchus AP, et

al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553-561. doi:10.1001/jama.2018.21442. PMID: 30688979. (Probable dementia — primary endpoint — NOT significantly reduced; MCI and combined MCI+dementia reduced.)

• [R21] Baker LD, Manson JE, Rapp SR, et al. *Effects of cocoa extract and a multivitamin on cognitive

function: a randomized clinical trial (COSMOS-Mind). Alzheimers Dement. 2023;19(4):1308-1319. doi:10.1002/alz.12767. PMID: 36102337. (Cocoa extract no effect; daily multivitamin modestly improved global cognition vs placebo — emerging.)*

• [R22] SPRINT Research Group; Wright JT Jr, Williamson JD, et al. *A randomized trial of intensive versus

standard blood-pressure control.* N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939. PMID:

1. (Intensive BP control <120 vs <140 reduced major CV events and all-cause mortality.)
2. [R23] Lal H, Cunningham AL, Godeaux O, et al. *Efficacy of an adjuvanted herpes zoster subunit vaccine in

older adults (ZOE-50). N Engl J Med. 2015;372(22):2087-2096. doi:10.1056/NEJMoa1501184. PMID: 25916341. (Recombinant zoster vaccine ~97% efficacy against shingles in adults ≥50.)*

• [R24] Papi A, Ison MG, Langley JM, et al. *Respiratory syncytial virus prefusion F protein vaccine in

older adults. N Engl J Med. 2023;388(7):595-608. doi:10.1056/NEJMoa2209604. PMID: 36791160. (RSVPreF3 OA vaccine efficacious against RSV lower-respiratory disease in adults ≥60.)*

• [R25] Cholesterol Treatment Trialists' Collaboration. *Efficacy and safety of statin therapy in older

people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-415. doi:10.1016/S0140-6736(18)31942-1. PMID: 30712900. (Statins reduce major vascular events per 1 mmol/L LDL reduction across ages, including older adults.)*

• [R26] Demicheli V, Jefferson T, Di Pietrantonj C, et al. *Vaccines for preventing influenza in the

elderly. Cochrane Database Syst Rev. 2018;2(2):CD004876. doi:10.1002/14651858.CD004876.pub4. PMID: 29388197. (Probably reduces influenza/ILI in adults ≥65; mortality evidence very low-certainty.)*

• [R27] Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell

Metab. 2016;23(6):1060-1065. doi:10.1016/j.cmet.2016.05.011. PMID: 27304507. (Rationale/design for the TAME trial; anti-aging efficacy in humans unproven, to be tested.)

• [R28] Iqbal T, Nakagawa T. The therapeutic perspective of NAD⁺ precursors in age-related diseases.

Biochem Biophys Res Commun. 2024;702:149590. doi:10.1016/j.bbrc.2024.149590. PMID: 38340651. (NAD⁺ precursors raise NAD⁺ but human clinical benefit for age-related disease is not established.)

Clickable identifiers: R1 WHO world report on ageing and health · R2 WHO 2020 physical activity guidelines · R3 Physical Activity Guidelines for Americans · R4 accelerometry PA & mortality · R5 cardiorespiratory fitness & mortality · R6 exercise in frail elderly (RCT) · R7 progressive resistance training (Cochrane) · R8 exercise for preventing falls (Cochrane) · R9 frailty phenotype · R10 sarcopenia EWGSOP2 · R11 PROT-AGE protein in older adults · R12 PREDIMED Mediterranean diet · R13 BMI & mortality in older adults · R14 vitamin D & fractures (VITAL) · R15 FINGER multidomain trial60461-5) · R16 Lancet Commission on dementia 202401296-0) · R17 ACTIVE cognitive training · R18 social relationships & mortality · R19 loneliness & isolation & mortality · R20 SPRINT MIND (BP & dementia) · R21 COSMOS-Mind (multivitamin & cognition) · R22 SPRINT (intensive BP control) · R23 zoster vaccine ZOE-50 · R24 RSV vaccine in older adults · R25 statins in older people (CTT)31942-1) · R26 influenza vaccine in the elderly (Cochrane) · R27 metformin to target aging (TAME) · R28 NAD⁺ precursors in age-related disease

21. Suggested Version Number

Version 1.0 (review-hardened) — sign-off recorded 2026-07-03. This monograph completed Phases 1–5 and cleared the Quality Gate; scientific + medical sign-off has certified it as "1.0 (review-hardened)," live in Foundations.

• A minor update (1.1) would attach additional dedicated references (e.g., World-Wide FINGERS results as

they publish, or a dedicated sensory-health reference), or confirm an identifier — none of which changes a verdict.

• A major update (2.0) would follow any change to a verdict or a headline confidence rating — for

example, a positive TAME trial upgrading anti-aging pharmacotherapy (claim-14), a multidomain trial reducing dementia incidence (claim-6/claim-7), or a trial reversing the vitamin-D fracture null (claim-15).

Never rewrite history: prior versions are preserved, changes documented, and any change in confidence explained.